Notably, a recent clinical study revealed for the first time a significant decrease of the dermatological mRSS score in SSc patients treated with a bi-specific antibody targeting IL-4 and IL-13 [60]; these findings further support the strategy of targeting multiple pathways in a complex disease like SSc. This evidence concerns the gene IL13 and systemic sclerosis.